BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
JaeIn Park1,#, Jae-Hyun Jang1,#, Geun-Soo Park1, Yunro Chung2, Hye Jin You3, Jae-Hong Kim1,*
1Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, South Korea,
2Department of Biomedical Informatics, Arizona State University, Scottsdale, AZ 85259, USA,
3Translational Research Branch, Division of Translational Science, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi 10408, South Korea
Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.
Abstract, Accepted Manuscript(in press) [Submitted on June 14, 2018, Accepted on June 14, 2018]
  Copyright © KSBMB. All rights reserved. / Powered by, Ltd